Home＞ACADEMIA
DPP-4 Inhibitor Prevents Deterioration in Cardiac Diastolic Function in Diabetes Patients: Research Sub-Analysis(May.26.2017)
The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin significantly inhibited deterioration in cardiac diastolic function in diabetes patients, according to results of a clinical research sub-analysis announced by Saga University on May 24 ...
(LOG IN FOR FULL STORY)
-
-
Nephrology Society to Build Database, Biobank to Support Drug Discovery; Some 20 Companies Interested in Collaboration
Oct.13
- AMED Study Group to Investigate Drugs to Recommend in Elderly Depression Patients; Findings to Be Reflected in New Guidelines Sep.07
- Over 150 Clinical Trials of Epigenetic Drugs, Some with Novel Mechanisms of Action, Underway Worldwide Aug.31
- Opdivo-Induced Myasthenia Gravis Tends to Become Severe: Keio Researchers Aug.21
- Japan Gastric Cancer Association to Wait for Opdivo Nod before Guidelines Update, Keytruda Won’t Make It This Time Aug.16
- Eisai Opts to Codevelop Biogen’s Aducanumab; New MS Copromotion Scheme Sealed(Oct.24)
- Shionogi Ups Earnings Outlook on Milestone Scheme Change(Oct.24)
- AZ’s Olaparib Filed for Breast Cancer in 2nd Submission(Oct.24)
- Mitsubishi Tanabe to Focus on US Approval for VLP Seasonal Flu Vaccine; Aims at 100 Billion Yen Sales for Vaccine Business by FY2030(Oct.24)
- Conditional Early Approval System Gets Underway: MHLW(Oct.23)
